173 related articles for article (PubMed ID: 23844574)
21. Optimization of a Screening Hit toward M2912, an Oral Tankyrase Inhibitor with Antitumor Activity in Colorectal Cancer Models.
Buchstaller HP; Anlauf U; Dorsch D; Kögler S; Kuhn D; Lehmann M; Leuthner B; Lodholz S; Musil D; Radtki D; Rettig C; Ritzert C; Rohdich F; Schneider R; Wegener A; Weigt S; Wilkinson K; Esdar C
J Med Chem; 2021 Jul; 64(14):10371-10392. PubMed ID: 34255518
[TBL] [Abstract][Full Text] [Related]
22. Structure-activity relationships of 2-arylquinazolin-4-ones as highly selective and potent inhibitors of the tankyrases.
Nathubhai A; Haikarainen T; Hayward PC; Muñoz-Descalzo S; Thompson AS; Lloyd MD; Lehtiö L; Threadgill MD
Eur J Med Chem; 2016 Aug; 118():316-27. PubMed ID: 27163581
[TBL] [Abstract][Full Text] [Related]
23. Development and structural analysis of adenosine site binding tankyrase inhibitors.
Haikarainen T; Waaler J; Ignatev A; Nkizinkiko Y; Venkannagari H; Obaji E; Krauss S; Lehtiö L
Bioorg Med Chem Lett; 2016 Jan; 26(2):328-333. PubMed ID: 26706174
[TBL] [Abstract][Full Text] [Related]
24. Zoning in on Tankyrases: A Brief Review on the Past, Present and Prospective Studies.
Peters XQ; Malinga TH; Agoni C; Olotu FA; Soliman MES
Anticancer Agents Med Chem; 2019; 19(16):1920-1934. PubMed ID: 31648650
[TBL] [Abstract][Full Text] [Related]
25. Discovery of potent and selective nonplanar tankyrase inhibiting nicotinamide mimics.
Nkizinkiko Y; Suneel Kumar BVS; Jeankumar VU; Haikarainen T; Koivunen J; Madhuri C; Yogeeswari P; Venkannagari H; Obaji E; Pihlajaniemi T; Sriram D; Lehtiö L
Bioorg Med Chem; 2015 Aug; 23(15):4139-4149. PubMed ID: 26183543
[TBL] [Abstract][Full Text] [Related]
26. Tankyrase inhibitors as therapeutic targets for cancer.
Kamal A; Riyaz S; Srivastava AK; Rahim A
Curr Top Med Chem; 2014; 14(17):1967-76. PubMed ID: 25262803
[TBL] [Abstract][Full Text] [Related]
27. Structural basis of selective inhibition of human tankyrases.
Narwal M; Venkannagari H; Lehtiö L
J Med Chem; 2012 Feb; 55(3):1360-7. PubMed ID: 22233320
[TBL] [Abstract][Full Text] [Related]
28. Novel, potent, selective, and orally bioavailable human betaII-tryptase inhibitors.
Sperandio D; Tai VW; Lohman J; Hirschbein B; Mendonca R; Lee CS; Spencer JR; Janc J; Nguyen M; Beltman J; Sprengeler P; Scheerens H; Lin T; Liu L; Gadre A; Kellogg A; Green MJ; McGrath ME
Bioorg Med Chem Lett; 2006 Aug; 16(15):4085-9. PubMed ID: 16725321
[TBL] [Abstract][Full Text] [Related]
29. The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.
Blackie JA; Bloomer JC; Brown MJ; Cheng HY; Elliott RL; Hammond B; Hickey DM; Ife RJ; Leach CA; Lewis VA; Macphee CH; Milliner KJ; Moores KE; Pinto IL; Smith SA; Stansfield IG; Stanway SJ; Taylor MA; Theobald CJ; Whittaker CM
Bioorg Med Chem Lett; 2002 Sep; 12(18):2603-6. PubMed ID: 12182870
[TBL] [Abstract][Full Text] [Related]
30. Tankyrase 1 Inhibitors with Drug-like Properties Identified by Screening a DNA-Encoded Chemical Library.
Samain F; Ekblad T; Mikutis G; Zhong N; Zimmermann M; Nauer A; Bajic D; Decurtins W; Scheuermann J; Brown PJ; Hall J; Gräslund S; Schüler H; Neri D; Franzini RM
J Med Chem; 2015 Jun; 58(12):5143-9. PubMed ID: 26061013
[TBL] [Abstract][Full Text] [Related]
31. Application of two-dimensional binary fingerprinting methods for the design of selective Tankyrase I inhibitors.
Muddukrishna BS; Pai V; Lobo R; Pai A
Mol Divers; 2018 May; 22(2):359-381. PubMed ID: 29168093
[TBL] [Abstract][Full Text] [Related]
32. Discovery of tankyrase inhibiting flavones with increased potency and isoenzyme selectivity.
Narwal M; Koivunen J; Haikarainen T; Obaji E; Legala OE; Venkannagari H; Joensuu P; Pihlajaniemi T; Lehtiö L
J Med Chem; 2013 Oct; 56(20):7880-9. PubMed ID: 24116873
[TBL] [Abstract][Full Text] [Related]
33. Discovery of potent, selective and orally bioavailable triaryl-sulfonamide based PTP1B inhibitors.
Patel D; Jain M; Shah SR; Bahekar R; Jadav P; Joharapurkar A; Dhanesha N; Shaikh M; Sairam KV; Kapadnis P
Bioorg Med Chem Lett; 2012 Jan; 22(2):1111-7. PubMed ID: 22189136
[TBL] [Abstract][Full Text] [Related]
34. Fragment-based ligand design of novel potent inhibitors of tankyrases.
Larsson EA; Jansson A; Ng FM; Then SW; Panicker R; Liu B; Sangthongpitag K; Pendharkar V; Tai SJ; Hill J; Dan C; Ho SY; Cheong WW; Poulsen A; Blanchard S; Lin GR; Alam J; Keller TH; Nordlund P
J Med Chem; 2013 Jun; 56(11):4497-508. PubMed ID: 23672613
[TBL] [Abstract][Full Text] [Related]
35. Sighting of tankyrase inhibitors by structure- and ligand-based screening and in vitro approach.
Kirubakaran P; Arunkumar P; Premkumar K; Muthusamy K
Mol Biosyst; 2014 Oct; 10(10):2699-712. PubMed ID: 25091558
[TBL] [Abstract][Full Text] [Related]
36. A novel yeast cell-based screen identifies flavone as a tankyrase inhibitor.
Yashiroda Y; Okamoto R; Hatsugai K; Takemoto Y; Goshima N; Saito T; Hamamoto M; Sugimoto Y; Osada H; Seimiya H; Yoshida M
Biochem Biophys Res Commun; 2010 Apr; 394(3):569-73. PubMed ID: 20214890
[TBL] [Abstract][Full Text] [Related]
37. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors.
Kim CU; Lew W; Williams MA; Wu H; Zhang L; Chen X; Escarpe PA; Mendel DB; Laver WG; Stevens RC
J Med Chem; 1998 Jul; 41(14):2451-60. PubMed ID: 9651151
[TBL] [Abstract][Full Text] [Related]
38. Tankyrases as drug targets.
Lehtiö L; Chi NW; Krauss S
FEBS J; 2013 Aug; 280(15):3576-93. PubMed ID: 23648170
[TBL] [Abstract][Full Text] [Related]
39. Scaffold hopping approach on the route to selective tankyrase inhibitors.
Liscio P; Carotti A; Asciutti S; Ferri M; Pires MM; Valloscuro S; Ziff J; Clark NR; Macchiarulo A; Aaronson SA; Pellicciari R; Camaioni E
Eur J Med Chem; 2014 Nov; 87():611-23. PubMed ID: 25299683
[TBL] [Abstract][Full Text] [Related]
40. Recent advances in the structure-based rational design of TNKSIs.
Zhan P; Song Y; Itoh Y; Suzuki T; Liu X
Mol Biosyst; 2014 Nov; 10(11):2783-99. PubMed ID: 25211064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
